Suggested remit: To appraise the clinical and cost effectiveness of fedratinib within its marketing authorisation for disease related splenomegaly or symptoms from myelofibrosis.
Status In progress
Process STA 2018
ID number 1501

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
03 April 2019 - 01 May 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 June 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance